5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
SELL | SELL | SELL | SELL | SELL |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 11.62▼ | 11.61▼ | 11.61▼ | 12.13▼ | 14.16▼ |
MA10 | 11.69▼ | 11.74▼ | 11.74▼ | 12.83▼ | 15.29▼ |
MA20 | 11.90▼ | 12.00▼ | 12.17▼ | 14.14▼ | 16.10▼ |
MA50 | 12.65▼ | 12.93▼ | 13.06▼ | 15.61▼ | N/A |
MA100 | 13.25▼ | 14.13▼ | 14.50▼ | 16.30▼ | N/A |
MA200 | 14.24▼ | 15.37▼ | 15.64▼ | N/A | N/A |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | -0.002▼ | -0.008▼ | -0.012▼ | -0.265▼ | -0.579▼ |
RSI | 19.959▼ | 21.576▼ | 21.483▼ | 23.310▼ | 32.771▼ |
STOCH | 14.448▼ | 9.623▼ | 7.452▼ | 6.944▼ | 11.395▼ |
WILL %R | -95.833▼ | -97.110▼ | -97.110▼ | -100.000▼ | -100.000▼ |
CCI | -180.247▼ | -149.327▼ | -143.148▼ | -140.858▼ | -236.154▼ |
Thursday, August 07, 2025 03:40 PM
TLX Investors with Losses Encouraged to Contact Hagens BermanSAN FRANCISCO, Aug. 08, 2025 (GLOBE NEWSWIRE) -- On July 23, 2025, investors i ...
|
Friday, August 01, 2025 07:03 AM
Pomerantz LLP is investigating claims on behalf of investors of Telix Pharmaceuticals Limited (“Telix” or the “Company”) (NASDAQ: TLX). Such investors are ...
|
Thursday, July 31, 2025 11:42 AM
The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Telix Pharmaceuticals Limited (“Telix” or “the Company”) ...
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
08/08/25 | 11.58 | 11.67 | 11.34 | 11.34 | 155,175 |
07/08/25 | 11.89 | 12.00 | 11.70 | 11.78 | 31,500 |
06/08/25 | 12.18 | 12.245 | 11.83 | 11.97 | 134,805 |
05/08/25 | 12.30 | 12.37 | 12.10 | 12.26 | 98,500 |
04/08/25 | 13.21 | 14.27 | 13.21 | 13.32 | 56,800 |
01/08/25 | 13.19 | 13.19 | 12.899 | 13.05 | 55,400 |
31/07/25 | 13.60 | 14.17 | 13.51 | 13.59 | 38,041 |
30/07/25 | 13.65 | 13.65 | 13.25 | 13.50 | 52,400 |
29/07/25 | 13.64 | 13.79 | 13.35 | 13.49 | 52,100 |
28/07/25 | 13.95 | 13.96 | 13.795 | 13.96 | 84,851 |
|
|
||||
|
|
||||
|
|